BioSpace News Archive

Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that it has entered into an agreement for the acquisition of the plasma collection center and certain related rights and assets from the privately-held Blood and Plasma Research, Inc (B&PR) of Beaumont, TX, USA.

Hillrom announced it has acquired contact-free continuous monitoring technology from EarlySense for terms including a cash consideration of $30 million, potential payments based on the achievement of certain commercial milestones, and a portion of Hillrom’s equity investment in EarlySense.

Celltrion Healthcare Canada Limited announced today that Health Canada has granted a notice of compliance (NOC) for Remsima™ SC (CT-P13 SC) in Canada for the treatment of adult patients with rheumatoid arthritis (RA).

Bristol Myers Squibb Application for Zeposia ® (ozanimod) for the Treatment of Ulcerative Colitis Accepted for Filing with Priority Review by U.S. Food and Drug Administration U.S. Food and Drug Administration assigned an action date of May 30, 2021

Constantine Kreatsoulas, PhD has joined Circle Pharma as its Vice President of Research Informatics and Computational Chemistry. Dr. Kreatsoulas joins Circle from GlaxoSmithKline (GSK) where he was the Head of US Molecular Design and Interim Head of Computational Toxicology.

Theralase Technologies Inc. has released the Company Quarterly Newsletter.

Dan Kastner , USA , has described an entirely new group of rare autoinflammatory diseases. His discoveries have brought new knowledge and led to the development of effective treatments.

Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly owned subsidiary Dialco Medical Inc. (“Dialco”), today announced the appointment of Dr. John Kellum, MD, MCCM as Chief Medical Officer.

Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced that Bill Lundberg, M.D., Chief Executive Officer, will participate in the following investor conferences:

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Philippe Drouet as Chief Commercial Officer.